echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Biogen Alzheimer's FDA judgment date approaches, capital market issues warning

    Biogen Alzheimer's FDA judgment date approaches, capital market issues warning

    • Last Update: 2021-06-18
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The US FDA will make a decision on Biogen's aducanumab on June 7
    .


    If approved, it will be the first treatment for Alzheimer's disease to be marketed in more than two decades


    The US FDA will make a decision on Biogen's aducanumab on June 7


    Analyst Iuri Struta said in the study that Biogen was not prepared for the patent cliffs of the three key multiple sclerosis drugs Tysabri, Tecfidera and Vumerity
    .


    "Uncertainty about the company's next revenue driver has weakened investor confidence


    At the same time, sales data show that the company's sales are declining rapidly
    .


    Bojian’s annual income has fallen for the first time in decades in 2020, and has dropped sharply from US$14.


    According to Struta, aducanumab is "the only real hope to avoid falling into the patent cliff
    .


    " The drug is designed to break down the accumulation of amyloid plaques that are thought to aggravate Alzheimer's disease


    Insightia stated that, apart from these efforts, Bojian does not have enough measures to maintain sales by 2024.
    Bojian CEO Michel Vounatsos aims to let Bojian's early investment and development drugs enter the market in 2024
    .


    Struta said, "Activist investors may question whether the management team is not performing well or following the wrong strategy


    Insightia pointed out that since Vounatsos took over in 2017, Bojian has only made one acquisition, that is, the acquisition of Nightstar Therapeutics for US$800 million.
    The company has brought promising drugs but has not solved recent problems
    .


    Insightia's possible alternative to Bojian: You can sell itself or merge with competitors


    It is not the first time for Bojian that activist investors have put pressure on the company
    .


    More than a decade ago, billionaire investor Carl Icahn argued with the company on the same issue, claiming that the company was poorly managed and underperformed compared to its peers


    Before the FDA made a decision on aducanumab, Brian Abrahams of RBC Capital Markets has warned investors to be prepared, not only for the substantial changes in Bojian’s stock, but also for other sales.
    Changes in the stocks of Haimer's disease treatment companies, and even those companies that may become the targets of Bojian's acquisition, including Eisai
    .

    Abrahams pointed out, "The FDA's upcoming decision on aducanumab is not only critical for Bojian, but may also have repercussions in the entire biopharmaceutical field, affecting the overall sentiment in the field, regulatory flexibility and business development dynamics.
    View
    .


    "



    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.